Concepedia

Author

Alexandre Coutté

Centre Hospitalier Universitaire Amiens-PicardieORCID

Also Known As

A Coutte, A Coutté, A. Coutte, A. Coutté, Alexandre COUTTE, Alexandre Coutt, Alexandre Coutte, Alexandre Coutté, Alexandre Coutté (798563), Coutte, Alexandre

156

Publications

1.7K

Citations

18

H-Index

64

Concepts

All Affiliations

Centre Hospitalier Universitaire Amiens-PicardieInstitut Gustave RoussyCentre Jean BernardCentre Hospitalier Universitaire de BesançonCentre Hospitalier de Bretagne Sud
AC

About

Alexandre Coutté is an author at Centre Hospitalier Universitaire Amiens-Picardie specializing in medicine, radiation oncology, and health sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

13

926

2

Health Sciences

11

11

732

3

Social Sciences

2

2

51

4

Language Studies

1

1

36

5

Public Health

1

1

163

Alexandre Coutté

×

23

Publications

1.4K

Citations

17

H-Index

YearCitations

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette,

The Lancet Oncology

2021

214

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun,

Annals of Oncology

2022

166

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard,

European Journal of Cancer

2020

163

Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial

Lionnel Geoffrois, Laurent Martin, D. De Raucourt,

Journal of Clinical Oncology

2018

143

Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study

Xu-Shan Sun, Yungan Tao, Christophe Le Tourneau,

The Lancet Oncology

2020

124

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

Yungan Tao, Anne Aupérin, Xu-Shan Sun,

European Journal of Cancer

2020

91

Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial

Yungan Tao, Anne Aupérin, Christian Sire,

Journal of Clinical Oncology

2018

77

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial

Jean Bourhis, Clément Sire, Yungan Tao,

Annals of Oncology

2020

63

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Kevin J. Harrington, Robert L. Ferris, Maura L. Gillison,

JAMA Oncology

2023

63

A phase II randomized trial of pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN): First results of the GORTEC 2015-01 “PembroRad” trial.

Xu Sun, Christian Sire, Yungan Tao,

Journal of Clinical Oncology

2018

53

Page 1